{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:17:35Z","timestamp":1790399855823,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1017459"],"award-info":[{"award-number":["OPP1017459"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12916-018-1033-7","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T03:38:30Z","timestamp":1522813110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study"],"prefix":"10.1186","volume":"16","author":[{"given":"Conor Duncan","family":"Tweed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve Helen","family":"Wills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Diacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl E.","family":"Louw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Mendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lerato","family":"Mohapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Nunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P. J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Spigelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. H.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"1033_CR1","first-page":"S231","volume":"3","author":"W Fox","year":"1999","unstructured":"Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946\u20131986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3:S231\u201379.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(95)90468-9","volume":"345","author":"I Mitchell","year":"1995","unstructured":"Mitchell I, Wendon J, Fitt S, Williams R. Anti-tuberculous therapy and acute liver failure. Lancet. 1995;345:555\u20136.","journal-title":"Lancet"},{"key":"1033_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","volume":"23","author":"A Tostmann","year":"2008","unstructured":"Tostmann A, Boeree MJ, Aarnoutse RE, de Lange W, Van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23:192\u2013202.","journal-title":"J Gastroenterol Hepatol"},{"key":"1033_CR4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/TROG_20113203_167","volume":"32","author":"H Devarbhavi","year":"2011","unstructured":"Devarbhavi H. Antituberculosis drug-induced liver injury: current perspective. Trop Gastroenterol. 2011;32:167\u201374.","journal-title":"Trop Gastroenterol"},{"key":"1033_CR5","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1183\/09031936.95.08081384","volume":"8","author":"NP Thompson","year":"1995","unstructured":"Thompson NP, Caplin ME, Hamilton MI, Gillespie SH, Clarke SW, Burroughs AK, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J. 1995;8:1384\u20138.","journal-title":"Eur Respir J"},{"key":"1033_CR6","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","volume":"174","author":"JJ Saukkonen","year":"2006","unstructured":"Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935\u201352.","journal-title":"Am J Respir Crit Care Med"},{"key":"1033_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.5588\/ijtld.14.0155","volume":"18","author":"H Chou","year":"2014","unstructured":"Chou H, Lin S, Chen W, Ke W, Chao P, Hsiao F. Monitoring liver function among patients who initiated anti-tuberculosis drugs in Taiwan, 2000\u20132011. Int J Tuberc Lung Dis. 2014;18:1245\u201351.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR8","first-page":"534","volume":"9","author":"JR Tost","year":"2005","unstructured":"Tost JR, Vidal R, Cayl\u00e0 J, D\u00edaz-Cabanela D, Jim\u00e9nez A, Broquetas JM, et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis. 2005;9:534\u201340.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR9","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","volume":"167","author":"D Yee","year":"2003","unstructured":"Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1033_CR10","first-page":"699","volume":"6","author":"MD Teleman","year":"2002","unstructured":"Teleman MD, Chee CBE, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis. 2002;6:699\u2013705.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5588\/ijtld.13.0545","volume":"18","author":"HJ Shin","year":"2014","unstructured":"Shin HJ, Lee HS, Kim YI, Lim SC, Jung JP, Ko YC, et al. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Int J Tuberc Lung Dis. 2014;18:347\u201351.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.5588\/ijtld.12.0782","volume":"17","author":"CC Shu","year":"2013","unstructured":"Shu CC, Lee CH, Lee MC, Wang JY, Yu CJ, Lee LN. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis. 2013;17:934\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR13","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/thx.53.3.176","volume":"53","author":"P Ormerod","year":"1998","unstructured":"Ormerod P, Campbell I, Novelli V, Pozniak A, Davies P, Skinner C, et al. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 1998;53:536\u201348.","journal-title":"Thorax"},{"key":"1033_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/thx.51.2.111","volume":"51","author":"P Ormerod","year":"1996","unstructured":"Ormerod P, Skinner C, Wales J. Hepatotoxicity of antituberculosis drugs. Thorax. 1996;51:111\u20133.","journal-title":"Thorax"},{"key":"1033_CR15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/1471-2458-12-454","volume":"12","author":"S Wu","year":"2012","unstructured":"Wu S, Xia Y, Lv X, Zhang Y, Tang S, Yang Z, et al. Effect of scheduled monitoring of liver function during anti-tuberculosis treatment in a retrospective cohort in China. BMC Public Health. 2012;12:454.","journal-title":"BMC Public Health"},{"key":"1033_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1164\/rccm.201105-0850OC","volume":"185","author":"A Singanayagam","year":"2012","unstructured":"Singanayagam A, Sridhar S, Dhariwal J, Abdel-Aziz D, Munro K, Connell DW, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med. 2012;185:653\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1033_CR17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371:1577\u201387.","journal-title":"N Engl J Med"},{"key":"1033_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806\u201315.","journal-title":"Clin Pharmacol Ther"},{"key":"1033_CR19","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46:1323\u201330.","journal-title":"J Clin Epidemiol"},{"key":"1033_CR20","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","volume":"46","author":"C Benichou","year":"1993","unstructured":"Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331\u20136.","journal-title":"J Clin Epidemiol"},{"key":"1033_CR21","unstructured":"Treatment of tuberculosis guidelines. 4th ed. Geneva: World Health Organization; 2010."},{"key":"1033_CR22","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1164\/rccm.201112-2174ED","volume":"185","author":"JJ Saukkonen","year":"2012","unstructured":"Saukkonen JJ, Powell K, Jereb JA. Monitoring for tuberculosis drug hepatotoxicity: moving from opinion to evidence. Am J Respir Crit Care Med. 2012;185:598\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1033_CR23","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/liv.12988","volume":"36","author":"L Dara","year":"2016","unstructured":"Dara L, Liu Z-X, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36:158\u201365.","journal-title":"Liver Int"},{"key":"1033_CR24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","volume":"281","author":"CM Nolan","year":"2012","unstructured":"Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy. JAMA. 2012;281:1014\u20138.","journal-title":"JAMA"},{"key":"1033_CR25","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/hep.23534","volume":"51","author":"R Kumar","year":"2010","unstructured":"Kumar R, Shalimar BV, Khanal S, Sreenivas V, Gupta SD, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665\u201374.","journal-title":"Hepatology"},{"key":"1033_CR26","unstructured":"Global hepatitis report. Geneva: World Health Organization; 2017."},{"key":"1033_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/thx.2006.058867","volume":"61","author":"RAM Breen","year":"2006","unstructured":"Breen RAM, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax. 2006;61:791\u20134.","journal-title":"Thorax"},{"key":"1033_CR28","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","volume":"157","author":"JR Ungo","year":"1998","unstructured":"Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"1033_CR29","doi-asserted-by":"crossref","unstructured":"Hassen Ali A, Belachew T, Yami A, Ayen WY. Anti-tuberculosis drug induced hepatotoxicity among TB\/HIV co-infected patients at Jimma University Hospital, Ethiopia: nested case-control study. PLoS One. 2013;8(5):e64622.","DOI":"10.1371\/journal.pone.0064622"},{"key":"1033_CR30","doi-asserted-by":"publisher","first-page":"e94271","DOI":"10.1371\/journal.pone.0094271","volume":"9","author":"G Yimer","year":"2014","unstructured":"Yimer G, Gry M, Amogne W, Makonnen E, Habtewold A, Petros Z, et al. Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patients. PLoS One. 2014;9:e94271.","journal-title":"PLoS One"},{"key":"1033_CR31","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1007\/s11033-012-2433-y","volume":"40","author":"H Du","year":"2013","unstructured":"Du H, Chen X, Fang Y, Yan O, Xu H, Li L, et al. Slow N -acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep. 2013;40:3591\u20136.","journal-title":"Mol Biol Rep"},{"key":"1033_CR32","first-page":"622","volume":"14","author":"S Lee","year":"2014","unstructured":"Lee S, Chung LS, Huang H, Chuang T, Liou Y, Wu LS. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis. 2014;14:622\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tube.2014.02.003","volume":"94","author":"N Singla","year":"2014","unstructured":"Singla N, Gupta D, Birbian N, Singh J. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis. 2014;94:293\u20138.","journal-title":"Tuberculosis"},{"key":"1033_CR34","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/jgh.12069","volume":"28","author":"JG Chamorro","year":"2013","unstructured":"Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda FM, Fr\u00edas A, et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol. 2013;28:323\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"1033_CR35","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.5588\/ijtld.12.0304","volume":"16","author":"R Deng","year":"2012","unstructured":"Deng R, Yang T, Wang Y, Tang N. CYP2E1 RsaI\/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis. 2012;16:1574\u201381.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR36","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","volume":"137","author":"RM Jasmer","year":"2002","unstructured":"Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med. 2002;137:640\u20137.","journal-title":"Ann Intern Med"},{"key":"1033_CR37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1164\/rccm.200209-998OC","volume":"167","author":"JE Stout","year":"2003","unstructured":"Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med. 2003;167:824\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"1033_CR38","first-page":"995","volume":"6","author":"AM Lee","year":"2002","unstructured":"Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis. 2002;6:995\u20131000.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1033_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1086\/422645","volume":"39","author":"R Van Hest","year":"2004","unstructured":"Van Hest R, Baars H, Kik S, Van Gerven P, Trompenaars MC, Kalisvaart N, et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004;39:488\u201396.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-018-1033-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T11:51:59Z","timestamp":1751543519000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-018-1033-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1033"],"URL":"https:\/\/doi.org\/10.1186\/s12916-018-1033-7","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,28]]},"assertion":[{"value":"23 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was granted for REMoxTB by the ethics board at University College London, and at each of the study sites:","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"46"}}